CASI Pharmaceuticals Inc [NASDAQ: CASI] stock went on a downward path that fall over -7.48% on previous day amounting to a one-week price decrease of less than -25.52%.
Over the last 12 months, CASI stock dropped by -56.27%. The one-year CASI Pharmaceuticals Inc stock forecast points to a potential upside of 66.0. The average equity rating for CASI stock is currently 1.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $21.07 million, with 15.49 million shares outstanding and 4.33 million shares in the current float. Compared to the average trading volume of 92.13K shares, CASI stock reached a trading volume of 237759 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on CASI Pharmaceuticals Inc [CASI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CASI shares is $4.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CASI stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BTIG Research have made an estimate for CASI Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 18, 2021. While these analysts kept the previous recommendation, Mizuho raised their target price to Buy. The new note on the price target was released on April 26, 2021, representing the official price target for CASI Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $5, while Oppenheimer analysts kept a Outperform rating on CASI stock.
The Average True Range (ATR) for CASI Pharmaceuticals Inc is set at 0.26, with the Price to Sales ratio for CASI stock in the period of the last 12 months amounting to 0.67.
CASI Stock Performance Analysis:
CASI Pharmaceuticals Inc [CASI] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -25.52. With this latest performance, CASI shares dropped by -28.70% in over the last four-week period, additionally sinking by -56.27% over the last 6 months – not to mention a drop of -56.27% in the past year of trading.
Insight into CASI Pharmaceuticals Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and CASI Pharmaceuticals Inc [CASI] shares currently have an operating margin of -128.26% and a Gross Margin at 41.31%. CASI Pharmaceuticals Inc’s Net Margin is presently recorded at -129.05%.
Return on Equity for this stock declined to -81.92%, with Return on Assets sitting at -81.92%.
CASI Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CASI. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for CASI Pharmaceuticals Inc go to 14.68%.
CASI Pharmaceuticals Inc [CASI] Institutonal Ownership Details
There are presently around $23.64%, or 40.38%% of CASI stock, in the hands of institutional investors.
